<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543139</url>
  </required_header>
  <id_info>
    <org_study_id>EBI_bipolar2015</org_study_id>
    <nct_id>NCT01543139</nct_id>
  </id_info>
  <brief_title>Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Trial of Combined Cytidine- and Creatine-Containing Drug and Dietary Supplement in the Treatment of the Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ewha Womans University</source>
  <brief_summary>
    <textblock>
      This proposed research is aimed to investigate the efficacy and safety of combined cytidine-
      and creatine-containing drug and dietary supplement in treating bipolar depression and to
      evaluate changes in relevant brain biochemical metabolism using magnetic resonance
      spectroscopy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The research project has been cancelled before any participants were enrolled.
  </why_stopped>
  <start_date type="Anticipated">December 1, 2015</start_date>
  <completion_date type="Anticipated">April 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in depressive symptom scores at 4 weeks</measure>
    <time_frame>Baseline and at 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in depressive symptom scores at 8 weeks</measure>
    <time_frame>Baseline and at 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in brain Glx (glutamate+glutamine) level assessed using magnetic resonance spectroscopy at baseline and 8 weeks</measure>
    <time_frame>Baseline and at 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in brain phosphocreatine level assessed using magnetic resonance spectroscopy at baseline and 8 weeks</measure>
    <time_frame>Baseline and at 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Valproate+Cytidine-+Creatine-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects with bipolar depression, treated with cytidine- and creatine-containing drug and dietary supplement in addition to valproate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproate+Cytidine-</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects with bipolar depression, treated with cytidine-containing drug and dietary supplement in addition to valproate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects with bipolar depression, treated with valproate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate+Cytidine-+Creatine-</intervention_name>
    <description>Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day</description>
    <arm_group_label>Valproate+Cytidine-+Creatine-</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate+Cytidine-</intervention_name>
    <description>Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day</description>
    <arm_group_label>Valproate+Cytidine-</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate</intervention_name>
    <description>Valproate: Week0-8: 300mg/day</description>
    <arm_group_label>Valproate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19-65 year-old male or female

          -  Bipolar depression diagnosed by Structured Clinical Interview for DSM-IV (SCID-IV)

          -  Written informed consent

        Exclusion Criteria:

          -  Present use of drugs for bipolar depression or any psychotropic medication

          -  Use of psychoactive medication that may affect brain imaging findings

          -  Diagnosis of any other axis I psychiatric disorder

          -  Presence of borderline personality disorder or antisocial personality disorder

          -  Presence of any major physical or neurological illness (e.g., epilepsy, multiple
             sclerosis, brain tumor, cerebrovascular disease, etc.)

          -  Hypersensitivity to divalproate, valpromide or diagnosis of porphyria

          -  Past or current liver disease, current severe liver or pancreas dysfunction

          -  Currently taking mefloquine

          -  Presence of alcohol or drug dependence, drug abuse

          -  Intelligence quotient below 80

          -  Contraindications to magnetic resonance imaging

          -  Women who are pregnant, breastfeeding, or planning pregnancy

          -  Allergy or intolerance to the study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Kyoon Lyoo, MD, PhD, MMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ewha Womans University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ewha Womans University</investigator_affiliation>
    <investigator_full_name>In Kyoon Lyoo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bipolar Depression</keyword>
  <keyword>Magnetic resonance spectroscopy</keyword>
  <keyword>Cytidine-</keyword>
  <keyword>Creatine-</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

